Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jul
05
Today In Oncology
Addition of Glofitamab to R-CHOP or Pola-R-CHP  in Younger Patients With High-Risk LBCL
FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma
Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo